ubiquinol-cytochrome c reductase binding protein pseudogene 1Genealiases: []
Q-omics provides the consensus-scored UQCRBP1 profile across patient tissues and cancer cell-line models. UQCRBP1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, UQCRBP1 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, UQCRBP1 RNA expression shows 11,364 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KICH, COAD, and UVM as cancer lineages where UQCRBP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UQCRBP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UQCRBP1 survival associations across molecular data types. UQCRBP1 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UQCRBP1 RNA expression–survival associations across cancer types. High UQCRBP1 expression shows unfavorable associations in KICH, UVM, OV, LIHC and STAD, but favorable associations in BLCA. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for UQCRBP1 RNA expression.
This table summarizes UQCRBP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for UQCRBP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UQCRBP1 shows higher tumor expression in COAD, LIHC, BRCA, KICH, HNSC and LUAD. The COAD box plot shows higher UQCRBP1 RNA expression in tumor versus normal tissue (log2 FC = +1.164, t-test p < 0.001).
This table shows molecular features associated with UQCRBP1 in patient tissues and cancer cell lines. In patient samples, UQCRBP1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, UQCRBP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC.
